CN101795675A - 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送 - Google Patents

使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送 Download PDF

Info

Publication number
CN101795675A
CN101795675A CN200780042460A CN200780042460A CN101795675A CN 101795675 A CN101795675 A CN 101795675A CN 200780042460 A CN200780042460 A CN 200780042460A CN 200780042460 A CN200780042460 A CN 200780042460A CN 101795675 A CN101795675 A CN 101795675A
Authority
CN
China
Prior art keywords
people
delivery system
drug delivery
reagent
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780042460A
Other languages
English (en)
Chinese (zh)
Inventor
A·安德里蒙
H-C·于盖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Da Volterra SAS
Original Assignee
Da Volterra SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra SAS filed Critical Da Volterra SAS
Publication of CN101795675A publication Critical patent/CN101795675A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200780042460A 2006-11-17 2007-11-16 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送 Pending CN101795675A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85959906P 2006-11-17 2006-11-17
US85960006P 2006-11-17 2006-11-17
US60/859,599 2006-11-17
US60/859,600 2006-11-17
PCT/EP2007/062475 WO2008059062A1 (fr) 2006-11-17 2007-11-16 Distribution colique à l'aide de billes zn/pectine avec un revêtement d'eudragit

Publications (1)

Publication Number Publication Date
CN101795675A true CN101795675A (zh) 2010-08-04

Family

ID=39181811

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780042460A Pending CN101795675A (zh) 2006-11-17 2007-11-16 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送

Country Status (7)

Country Link
EP (1) EP2081557A1 (fr)
JP (1) JP2010510196A (fr)
CN (1) CN101795675A (fr)
AU (1) AU2007321111A1 (fr)
BR (1) BRPI0719319A2 (fr)
CA (1) CA2678131A1 (fr)
WO (1) WO2008059062A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018090266A1 (fr) * 2016-11-17 2018-05-24 上海交通大学医学院 Système d'administration par voie orale ciblant le côlon, et procédé de préparation et application de ce dernier
CN109562147A (zh) * 2016-06-28 2019-04-02 合成生物制品有限公司 保护微生物组免受口服抗生素
CN110075130A (zh) * 2013-03-14 2019-08-02 塞拉拜姆有限责任公司 益生生物和/或治疗剂的靶向胃肠道递送
CN110381928A (zh) * 2017-02-01 2019-10-25 弗劳恩霍夫应用研究促进协会 用于肿瘤治疗剂和肿瘤诊断剂的选择性释放系统以及用于肿瘤组织的生物传感器

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033724A1 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation du peptide natriurétique de type c, seul ou en combinaison avec un neuropeptide af comme agent thérapeutique
CA2698985A1 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide comme agent therapeutique
CA2698768A1 (fr) * 2007-09-11 2009-04-02 Dorian Bevec Utilisation d'un peptide en tant qu'agent therapeutique
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
SI2538930T1 (sl) * 2010-02-23 2016-10-28 Da Volterra Formulacije za oralno dostavo adsorbentov v črevesju
US20130089585A1 (en) * 2010-04-08 2013-04-11 Merz Pharma Gmbh & Co., Kgaa Filler comprising beads
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
CA2910601A1 (fr) * 2013-04-26 2014-10-30 La Jolla Pharmaceutical Company Compositions et procedes de traitement de l'insuffisance renale
WO2015066212A2 (fr) * 2013-10-31 2015-05-07 University Of Hawaii Inhibiteurs de la calpaïne destinés au traitement de la maladie inflammatoire chronique de l'intestin et du cancer colorectal
ES2771749T3 (es) 2013-12-18 2020-07-07 The George Washington Univ A Congressionally Chartered Not For Profit Corporation Angiotensina II en combinación para el tratamiento de hipotensión
CN105828809B (zh) 2013-12-20 2019-10-29 费森尤斯卡比德国有限公司 包含脂质和活性药剂的具有聚合物涂层的微胶囊
WO2016037745A1 (fr) * 2014-09-11 2016-03-17 Gelita Ag Particules de gélatine/pectine
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
WO2017120438A1 (fr) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Méthodes d'administration d'angiotensine ii
WO2018191678A1 (fr) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Méthodes d'administration d'angiotensine ii

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ATE468846T1 (de) * 2004-03-26 2010-06-15 Lek Pharmaceuticals Magenresistente pharmazeutische dosierform mit n- (2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d- glutaminsäure (lk-423)
CA2608505C (fr) * 2005-05-18 2013-12-24 Da Volterra Administration colonique d'adsorbants

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110075130A (zh) * 2013-03-14 2019-08-02 塞拉拜姆有限责任公司 益生生物和/或治疗剂的靶向胃肠道递送
CN109562147A (zh) * 2016-06-28 2019-04-02 合成生物制品有限公司 保护微生物组免受口服抗生素
CN109562147B (zh) * 2016-06-28 2023-09-01 特里瓦生物制剂有限公司 保护微生物组免受口服抗生素
WO2018090266A1 (fr) * 2016-11-17 2018-05-24 上海交通大学医学院 Système d'administration par voie orale ciblant le côlon, et procédé de préparation et application de ce dernier
CN108401418A (zh) * 2016-11-17 2018-08-14 上海交通大学医学院 口服结肠靶向的递送系统及其制备方法和应用
CN108401418B (zh) * 2016-11-17 2023-05-26 上海交通大学医学院 口服结肠靶向的递送系统及其制备方法和应用
CN110381928A (zh) * 2017-02-01 2019-10-25 弗劳恩霍夫应用研究促进协会 用于肿瘤治疗剂和肿瘤诊断剂的选择性释放系统以及用于肿瘤组织的生物传感器

Also Published As

Publication number Publication date
BRPI0719319A2 (pt) 2014-02-04
WO2008059062A1 (fr) 2008-05-22
EP2081557A1 (fr) 2009-07-29
AU2007321111A1 (en) 2008-05-22
CA2678131A1 (fr) 2008-05-22
JP2010510196A (ja) 2010-04-02

Similar Documents

Publication Publication Date Title
CN101795675A (zh) 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
US20080317666A1 (en) Colonic Delivery of Active Agents
US20080124279A1 (en) Colonic delivery using Zn/pectin beads with a Eudragit coating
Zeeshan et al. Advances in orally-delivered pH-sensitive nanocarrier systems; an optimistic approach for the treatment of inflammatory bowel disease
Moroz et al. Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
KR101080577B1 (ko) 활성성분의 결장 표적화 전달을 위한 제제
DE69735496T2 (de) Nukleinsäure zur Verwendung in Gentherapie, welche Therapie intestinale Zell-Expression der Gene involviert
CN111225686A (zh) 使用可摄入装置释放免疫调节剂治疗炎性疾病
CN112203669A (zh) 微生物组相关的免疫疗法
US8796203B2 (en) Use of tight junction antagonists to treat inflammatory bowel disease
KR20190127984A (ko) 지연 방출형 약물 제형
CN1997352A (zh) 含粘膜粘附性聚合物的酶、微生物和抗体的控释制剂
CN102014880A (zh) 治疗性磷酸钙颗粒及其制备和使用方法
Prasanth et al. Colon specific drug delivery systems: a review on various pharmaceutical approaches
JP2002521346A (ja) 多糖類を利用した大腸選択性薬物伝達組成物および医薬製剤
US20220241383A1 (en) Alkaline phosphatase agents for treatment of neurodevelopmental disorders
CN102164618A (zh) 用于体内转染肠细胞的非病毒组合物和方法
US8273376B2 (en) Colonic delivery of metallo-dependent enzymes
US20220202721A1 (en) Articles and methods for administration of therapeutic agents
Duraivel et al. Peroral administration of peptides and proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100804